查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1604585

抗凝血酶市場：按配方、來源、類型、途徑和應用分類 - 2025-2030 年全球預測

Antithrombin Market by Formulation (Liquid, Lyophilized), Source (Goat Milk, Human), Type, Route, Application - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 187 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

2023年抗凝血酶市值為7.9609億美元，預計2024年將達到8.7687億美元，複合年成長率為10.24%，到2030年將達到15.7532億美元。

抗凝血酶是一種重要的血漿蛋白，透過抑制凝血酶和參與血液凝固過程的其他酵素來幫助調節血液凝固。抗凝血酶的需求源於其在降低與深層靜脈栓塞症、肺動脈栓塞和其他凝血障礙相關的風險以及預防異常血栓形成方面的重要作用。它主要用於治療藥物，特別是在涉及心肺體外迴圈和肝素治療的手術中，以幫助調節抗凝血作用。最終用途主要包括醫療機構、血液學研究人員和專注於抗凝血治療的製藥公司。抗凝血酶市場受到多種成長要素的影響，例如凝血障礙盛行率的增加以及促進重組蛋白藥物開發的生物技術的進步。擴大用於治療遺傳性抗凝血酶缺陷以及開發具有更高功效和遞送效果的新製劑的潛力正在增加。新興市場提供了醫療保健支出增加和血液疾病創新診斷技術開發等機會。然而，該市場面臨諸如高製造成本和嚴格的生技藥品監管要求等限制，這可能會延遲產品核可。生產重組蛋白的複雜性也構成了重大挑戰。該行業可以從合成生物學研究中受益，以降低生產成本、提高產量並創造更穩定的配方。提高抗凝血酶生物有效性和穩定性的藥物傳輸系統創新也可能推動市場成長。抗凝血酶市場是一個競爭激烈的市場，主要企業都專注於策略夥伴關係和研究合作，以擴大產品系列。總體而言，未來的市場開拓將取決於利用技術進步來開發具有成本效益和治療有效的抗凝血酶產品，同時克服監管和經濟挑戰。

主要市場統計
基準年[2023] 79609萬美元
預計年份 [2024] 87687萬美元
預測年份 [2030] 15.7532 億美元
複合年成長率（%） 10.24%

市場動態：揭示快速發展的抗凝血酶市場的關鍵市場洞察

抗凝血酶市場正因供需的動態交互作用而轉變。透過了解這些不斷變化的市場動態，公司可以準備好做出明智的投資決策、完善策略決策並抓住新的商機。全面了解這些趨勢可以幫助企業降低政治、地理、技術、社會和經濟領域的風險，同時消費行為及其對製造成本的影響以及對採購趨勢的影響。

  • 市場促進因素
    • 抗凝血酶缺乏增加，手術期間出血增加
    • 快速診斷測試的利用和抗凝血酶的需求
    • 提高消費者對血栓性疾病的認知
  • 市場限制因素
    • 抗凝血酶的資本集中生產
  • 市場機會
    • 抗凝血酵素藥物中擴大採用天然藥物
    • 開發具有成本效益的抗凝血酶生產程序的技術進步
  • 市場挑戰
    • 抗凝血酶缺乏症實驗室檢測的局限性

波特的五力：駕馭抗凝血酶市場的策略工具

波特的五力架構是了解抗凝血酶市場競爭格局的關鍵工具。波特的五力框架為評估公司的競爭地位和探索策略機會提供了清晰的方法。該框架可幫助公司評估市場動態並確定新業務的盈利。這些見解使公司能夠利用自己的優勢，解決弱點並避免潛在的挑戰，從而確保更強大的市場地位。

PESTLE分析：了解抗凝血酶市場的外部影響

外部宏觀環境因素在塑造抗凝血酶市場的績效動態方面發揮著至關重要的作用。對政治、經濟、社會、技術、法律和環境因素的分析提供了應對這些影響所需的資訊。透過調查 PESTLE 因素，公司可以更了解潛在的風險和機會。這種分析可以幫助公司預測法規、消費者偏好和經濟趨勢的變化，並幫助他們做出積極主動的決策。

市場佔有率分析 了解抗凝血酶市場的競爭狀況

抗凝血酶市場的詳細市場佔有率分析可以對供應商績效進行全面評估。公司可以透過比較收益、客戶群和成長率等關鍵指標來揭示其競爭地位。該分析揭示了市場集中、分散和整合的趨勢，為供應商提供了製定策略決策所需的洞察力，使他們能夠在日益激烈的競爭中佔有一席之地。

FPNV 定位矩陣抗凝血酶市場供應商的績效評估

FPNV定位矩陣是評估抗凝血酶市場供應商的重要工具。此矩陣允許業務組織根據供應商的商務策略和產品滿意度評估供應商，從而做出符合其目標的明智決策。這四個象限使您能夠清晰、準確地分類供應商，並確定最能滿足您的策略目標的合作夥伴和解決方案。

策略分析與建議繪製抗凝血酶市場的成功之路

抗凝血酶市場的策略分析對於旨在加強其在全球市場的影響力的公司至關重要。透過審查關鍵資源、能力和績效指標，公司可以識別成長機會並努力改進。這種方法使您能夠克服競爭環境中的挑戰，利用新的商機，並取得長期成功。

本報告對市場進行了全面分析，涵蓋關鍵重點領域：

1. 市場滲透率：對當前市場環境的詳細審查、主要企業的廣泛資料、對其在市場中的影響力和整體影響力的評估。

2. 市場開拓：辨識新興市場的成長機會，評估現有領域的擴張潛力，並提供未來成長的策略藍圖。

3. 市場多元化：分析近期產品發布、開拓地區、關鍵產業進展、塑造市場的策略投資。

4. 競爭評估與情報：徹底分析競爭格局，檢驗市場佔有率、業務策略、產品系列、認證、監理核准、專利趨勢、主要企業的技術進步等。

5. 產品開發與創新：重點在於有望推動未來市場成長的最尖端科技、研發活動和產品創新。

我們也回答重要問題，以幫助相關人員做出明智的決策：

1.目前的市場規模和未來的成長預測是多少？

2. 哪些產品、區隔市場和地區提供最佳投資機會？

3.塑造市場的主要技術趨勢和監管影響是什麼？

4.主要廠商的市場佔有率和競爭地位如何？

5. 推動供應商市場進入和退出策略的收益來源和策略機會是什麼？

目錄

第1章 前言

第2章調查方法

第3章執行摘要

第4章市場概況

第5章市場洞察

  • 市場動態
    • 促進因素
      • 抗凝血酶缺乏增加和術中出血增加
      • 快速診斷測試的利用和抗凝血酶的需求
      • 消費者對血栓性疾病的認知提高
    • 抑制因素
      • 抗凝血酶的資本密集型生產
    • 機會
      • 抗凝血酵素中天然物質的採用增加
      • 開發具有成本效益的抗凝血酶生產程序的技術進步
    • 任務
      • 抗凝血酶缺乏症臨床檢測的局限性
  • 市場區隔分析
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 經濟
    • 社群
    • 技術的
    • 合法地
    • 環境

第6章 處方抗凝血酶市場

  • 液體
  • 冷凍乾燥

第7章抗凝血酶市場：依來源分類

  • 羊奶
  • 人類

第8章抗凝血酶市場：依類型

  • 抗凝血物
  • 抗血小板藥
  • 溶栓藥物

第 9 章 抗凝血酶市場：按路線

  • 口服
  • 胃腸外的

第10章抗凝血酶市場：依應用分類

  • 診斷
  • 調查
  • 治療藥物

第11章美洲抗凝血酶市場

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第12章亞太地區抗凝血酶市場

  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第13章歐洲、中東和非洲的抗凝血酶市場

  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第14章競爭格局

  • 2023 年市場佔有率分析
  • FPNV 定位矩陣，2023
  • 競爭情境分析
  • 戰略分析和建議

公司名單

  • Bio-Techne Corporation
  • BioPharm Laboratories, LLC
  • CSL Limited
  • Diapharma Group, Inc.
  • European Medicines Agency
  • Genesis BioPharma
  • Grifols, SA
  • Kedrion SpA
  • Lee Biosolutions, Inc.
  • LFB USA, Inc.
  • Merck KGaA
  • Octapharma AG
  • Scripps Laboratories, Inc.
  • Siemens AG
  • SK Plasma
  • Takeda Pharmaceutical Company Limited
  • Thermo Fisher Scientific Inc.
  • WebMD, LLC
Product Code: MRR-4358BACA8223

The Antithrombin Market was valued at USD 796.09 million in 2023, expected to reach USD 876.87 million in 2024, and is projected to grow at a CAGR of 10.24%, to USD 1,575.32 million by 2030.

Antithrombin is a vital plasma protein that helps regulate blood coagulation by inhibiting thrombin and other enzymes involved in the clotting process. The necessity of antithrombin arises from its critical role in preventing abnormal clot formation, thereby mitigating risks associated with conditions like deep vein thrombosis, pulmonary embolism, and other coagulation disorders. It finds application primarily in therapeutics, particularly in surgeries involving cardiopulmonary bypass and during heparin therapy, where it helps to regulate anticoagulation. The end-use scope primarily includes healthcare facilities, researchers in hematology, and pharmaceutical companies focusing on anticoagulant therapies. The antithrombin market is influenced by several growth factors, including the increasing prevalence of coagulation disorders and advancements in biotechnology that facilitate the development of recombinant protein drugs. There is a growing potential in expanding its use in treating genetic antithrombin deficiency and developing novel formulations with enhanced efficacy and delivery. Opportunities exist in emerging markets with rising healthcare expenditures and the deployment of innovative diagnostics for blood disorders. However, the market faces limitations such as high production costs and stringent regulatory requirements for biologics, which can delay product approvals. The complexity of manufacturing recombinant proteins also poses significant challenges. The industry could benefit from research into synthetic biology to lower production costs, enhance yield, and create more stable antithrombin formulations. Innovations in drug delivery systems that improve the bioavailability and stability of antithrombin could also drive market growth. The nature of the antithrombin market is competitive, with key players focusing on strategic partnerships and research collaborations to expand their product portfolios. Overall, future market development hinges on overcoming regulatory and economic challenges while harnessing technological advancements to develop cost-effective and therapeutically potent antithrombin products.

KEY MARKET STATISTICS
Base Year [2023] USD 796.09 million
Estimated Year [2024] USD 876.87 million
Forecast Year [2030] USD 1,575.32 million
CAGR (%) 10.24%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Antithrombin Market

The Antithrombin Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Growing occurrence of antithrombin deficiency and increased bleeding during surgeries
    • Utilization of rapid diagnostic tests and need for antithrombin
    • Increasing awareness of the thrombotic disease among consumers
  • Market Restraints
    • Capital-intensive production of antithrombin
  • Market Opportunities
    • Rising adoption of natural agents in antithrombins
    • Technological advancements in the development of cost-effective procedures in the production of antithrombin
  • Market Challenges
    • Limitations of lab testing of antithrombin deficiency

Porter's Five Forces: A Strategic Tool for Navigating the Antithrombin Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Antithrombin Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Antithrombin Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Antithrombin Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Antithrombin Market

A detailed market share analysis in the Antithrombin Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Antithrombin Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Antithrombin Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Antithrombin Market

A strategic analysis of the Antithrombin Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Antithrombin Market, highlighting leading vendors and their innovative profiles. These include Bio-Techne Corporation, BioPharm Laboratories, LLC, CSL Limited, Diapharma Group, Inc., European Medicines Agency, Genesis BioPharma, Grifols, S.A., Kedrion S.p.A., Lee Biosolutions, Inc., LFB USA, Inc., Merck KGaA, Octapharma AG, Scripps Laboratories, Inc., Siemens AG, SK Plasma, Takeda Pharmaceutical Company Limited, Thermo Fisher Scientific Inc., and WebMD, LLC.

Market Segmentation & Coverage

This research report categorizes the Antithrombin Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Formulation, market is studied across Liquid and Lyophilized.
  • Based on Source, market is studied across Goat Milk and Human.
  • Based on Type, market is studied across Anticoagulant, Antiplatelet, and Thrombolytic Drugs.
  • Based on Route, market is studied across Oral and Parenteral.
  • Based on Application, market is studied across Diagnostics, Research, and Therapeutics.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Growing occurrence of antithrombin deficiency and increased bleeding during surgeries
      • 5.1.1.2. Utilization of rapid diagnostic tests and need for antithrombin
      • 5.1.1.3. Increasing awareness of the thrombotic disease among consumers
    • 5.1.2. Restraints
      • 5.1.2.1. Capital-intensive production of antithrombin
    • 5.1.3. Opportunities
      • 5.1.3.1. Rising adoption of natural agents in antithrombins
      • 5.1.3.2. Technological advancements in the development of cost-effective procedures in the production of antithrombin
    • 5.1.4. Challenges
      • 5.1.4.1. Limitations of lab testing of antithrombin deficiency
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Antithrombin Market, by Formulation

  • 6.1. Introduction
  • 6.2. Liquid
  • 6.3. Lyophilized

7. Antithrombin Market, by Source

  • 7.1. Introduction
  • 7.2. Goat Milk
  • 7.3. Human

8. Antithrombin Market, by Type

  • 8.1. Introduction
  • 8.2. Anticoagulant
  • 8.3. Antiplatelet
  • 8.4. Thrombolytic Drugs

9. Antithrombin Market, by Route

  • 9.1. Introduction
  • 9.2. Oral
  • 9.3. Parenteral

10. Antithrombin Market, by Application

  • 10.1. Introduction
  • 10.2. Diagnostics
  • 10.3. Research
  • 10.4. Therapeutics

11. Americas Antithrombin Market

  • 11.1. Introduction
  • 11.2. Argentina
  • 11.3. Brazil
  • 11.4. Canada
  • 11.5. Mexico
  • 11.6. United States

12. Asia-Pacific Antithrombin Market

  • 12.1. Introduction
  • 12.2. Australia
  • 12.3. China
  • 12.4. India
  • 12.5. Indonesia
  • 12.6. Japan
  • 12.7. Malaysia
  • 12.8. Philippines
  • 12.9. Singapore
  • 12.10. South Korea
  • 12.11. Taiwan
  • 12.12. Thailand
  • 12.13. Vietnam

13. Europe, Middle East & Africa Antithrombin Market

  • 13.1. Introduction
  • 13.2. Denmark
  • 13.3. Egypt
  • 13.4. Finland
  • 13.5. France
  • 13.6. Germany
  • 13.7. Israel
  • 13.8. Italy
  • 13.9. Netherlands
  • 13.10. Nigeria
  • 13.11. Norway
  • 13.12. Poland
  • 13.13. Qatar
  • 13.14. Russia
  • 13.15. Saudi Arabia
  • 13.16. South Africa
  • 13.17. Spain
  • 13.18. Sweden
  • 13.19. Switzerland
  • 13.20. Turkey
  • 13.21. United Arab Emirates
  • 13.22. United Kingdom

14. Competitive Landscape

  • 14.1. Market Share Analysis, 2023
  • 14.2. FPNV Positioning Matrix, 2023
  • 14.3. Competitive Scenario Analysis
  • 14.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Bio-Techne Corporation
  • 2. BioPharm Laboratories, LLC
  • 3. CSL Limited
  • 4. Diapharma Group, Inc.
  • 5. European Medicines Agency
  • 6. Genesis BioPharma
  • 7. Grifols, S.A.
  • 8. Kedrion S.p.A.
  • 9. Lee Biosolutions, Inc.
  • 10. LFB USA, Inc.
  • 11. Merck KGaA
  • 12. Octapharma AG
  • 13. Scripps Laboratories, Inc.
  • 14. Siemens AG
  • 15. SK Plasma
  • 16. Takeda Pharmaceutical Company Limited
  • 17. Thermo Fisher Scientific Inc.
  • 18. WebMD, LLC

LIST OF FIGURES

  • FIGURE 1. ANTITHROMBIN MARKET RESEARCH PROCESS
  • FIGURE 2. ANTITHROMBIN MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL ANTITHROMBIN MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL ANTITHROMBIN MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL ANTITHROMBIN MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL ANTITHROMBIN MARKET SIZE, BY FORMULATION, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL ANTITHROMBIN MARKET SIZE, BY FORMULATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL ANTITHROMBIN MARKET SIZE, BY SOURCE, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL ANTITHROMBIN MARKET SIZE, BY SOURCE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL ANTITHROMBIN MARKET SIZE, BY TYPE, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL ANTITHROMBIN MARKET SIZE, BY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL ANTITHROMBIN MARKET SIZE, BY ROUTE, 2023 VS 2030 (%)
  • FIGURE 13. GLOBAL ANTITHROMBIN MARKET SIZE, BY ROUTE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. GLOBAL ANTITHROMBIN MARKET SIZE, BY APPLICATION, 2023 VS 2030 (%)
  • FIGURE 15. GLOBAL ANTITHROMBIN MARKET SIZE, BY APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. AMERICAS ANTITHROMBIN MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. AMERICAS ANTITHROMBIN MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. UNITED STATES ANTITHROMBIN MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 19. UNITED STATES ANTITHROMBIN MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. ASIA-PACIFIC ANTITHROMBIN MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 21. ASIA-PACIFIC ANTITHROMBIN MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 22. EUROPE, MIDDLE EAST & AFRICA ANTITHROMBIN MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 23. EUROPE, MIDDLE EAST & AFRICA ANTITHROMBIN MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 24. ANTITHROMBIN MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 25. ANTITHROMBIN MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. ANTITHROMBIN MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL ANTITHROMBIN MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL ANTITHROMBIN MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL ANTITHROMBIN MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. ANTITHROMBIN MARKET DYNAMICS
  • TABLE 7. GLOBAL ANTITHROMBIN MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL ANTITHROMBIN MARKET SIZE, BY LIQUID, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL ANTITHROMBIN MARKET SIZE, BY LYOPHILIZED, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL ANTITHROMBIN MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL ANTITHROMBIN MARKET SIZE, BY GOAT MILK, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL ANTITHROMBIN MARKET SIZE, BY HUMAN, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL ANTITHROMBIN MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL ANTITHROMBIN MARKET SIZE, BY ANTICOAGULANT, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL ANTITHROMBIN MARKET SIZE, BY ANTIPLATELET, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL ANTITHROMBIN MARKET SIZE, BY THROMBOLYTIC DRUGS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL ANTITHROMBIN MARKET SIZE, BY ROUTE, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL ANTITHROMBIN MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL ANTITHROMBIN MARKET SIZE, BY PARENTERAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL ANTITHROMBIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL ANTITHROMBIN MARKET SIZE, BY DIAGNOSTICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL ANTITHROMBIN MARKET SIZE, BY RESEARCH, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL ANTITHROMBIN MARKET SIZE, BY THERAPEUTICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 24. AMERICAS ANTITHROMBIN MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 25. AMERICAS ANTITHROMBIN MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 26. AMERICAS ANTITHROMBIN MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 27. AMERICAS ANTITHROMBIN MARKET SIZE, BY ROUTE, 2018-2030 (USD MILLION)
  • TABLE 28. AMERICAS ANTITHROMBIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 29. AMERICAS ANTITHROMBIN MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 30. ARGENTINA ANTITHROMBIN MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 31. ARGENTINA ANTITHROMBIN MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 32. ARGENTINA ANTITHROMBIN MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 33. ARGENTINA ANTITHROMBIN MARKET SIZE, BY ROUTE, 2018-2030 (USD MILLION)
  • TABLE 34. ARGENTINA ANTITHROMBIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 35. BRAZIL ANTITHROMBIN MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 36. BRAZIL ANTITHROMBIN MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 37. BRAZIL ANTITHROMBIN MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 38. BRAZIL ANTITHROMBIN MARKET SIZE, BY ROUTE, 2018-2030 (USD MILLION)
  • TABLE 39. BRAZIL ANTITHROMBIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 40. CANADA ANTITHROMBIN MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 41. CANADA ANTITHROMBIN MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 42. CANADA ANTITHROMBIN MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 43. CANADA ANTITHROMBIN MARKET SIZE, BY ROUTE, 2018-2030 (USD MILLION)
  • TABLE 44. CANADA ANTITHROMBIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 45. MEXICO ANTITHROMBIN MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 46. MEXICO ANTITHROMBIN MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 47. MEXICO ANTITHROMBIN MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 48. MEXICO ANTITHROMBIN MARKET SIZE, BY ROUTE, 2018-2030 (USD MILLION)
  • TABLE 49. MEXICO ANTITHROMBIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 50. UNITED STATES ANTITHROMBIN MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 51. UNITED STATES ANTITHROMBIN MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 52. UNITED STATES ANTITHROMBIN MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 53. UNITED STATES ANTITHROMBIN MARKET SIZE, BY ROUTE, 2018-2030 (USD MILLION)
  • TABLE 54. UNITED STATES ANTITHROMBIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 55. UNITED STATES ANTITHROMBIN MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 56. ASIA-PACIFIC ANTITHROMBIN MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 57. ASIA-PACIFIC ANTITHROMBIN MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 58. ASIA-PACIFIC ANTITHROMBIN MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 59. ASIA-PACIFIC ANTITHROMBIN MARKET SIZE, BY ROUTE, 2018-2030 (USD MILLION)
  • TABLE 60. ASIA-PACIFIC ANTITHROMBIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 61. ASIA-PACIFIC ANTITHROMBIN MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 62. AUSTRALIA ANTITHROMBIN MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 63. AUSTRALIA ANTITHROMBIN MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 64. AUSTRALIA ANTITHROMBIN MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 65. AUSTRALIA ANTITHROMBIN MARKET SIZE, BY ROUTE, 2018-2030 (USD MILLION)
  • TABLE 66. AUSTRALIA ANTITHROMBIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 67. CHINA ANTITHROMBIN MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 68. CHINA ANTITHROMBIN MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 69. CHINA ANTITHROMBIN MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 70. CHINA ANTITHROMBIN MARKET SIZE, BY ROUTE, 2018-2030 (USD MILLION)
  • TABLE 71. CHINA ANTITHROMBIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 72. INDIA ANTITHROMBIN MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 73. INDIA ANTITHROMBIN MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 74. INDIA ANTITHROMBIN MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 75. INDIA ANTITHROMBIN MARKET SIZE, BY ROUTE, 2018-2030 (USD MILLION)
  • TABLE 76. INDIA ANTITHROMBIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 77. INDONESIA ANTITHROMBIN MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 78. INDONESIA ANTITHROMBIN MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 79. INDONESIA ANTITHROMBIN MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 80. INDONESIA ANTITHROMBIN MARKET SIZE, BY ROUTE, 2018-2030 (USD MILLION)
  • TABLE 81. INDONESIA ANTITHROMBIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 82. JAPAN ANTITHROMBIN MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 83. JAPAN ANTITHROMBIN MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 84. JAPAN ANTITHROMBIN MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 85. JAPAN ANTITHROMBIN MARKET SIZE, BY ROUTE, 2018-2030 (USD MILLION)
  • TABLE 86. JAPAN ANTITHROMBIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 87. MALAYSIA ANTITHROMBIN MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 88. MALAYSIA ANTITHROMBIN MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 89. MALAYSIA ANTITHROMBIN MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 90. MALAYSIA ANTITHROMBIN MARKET SIZE, BY ROUTE, 2018-2030 (USD MILLION)
  • TABLE 91. MALAYSIA ANTITHROMBIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 92. PHILIPPINES ANTITHROMBIN MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 93. PHILIPPINES ANTITHROMBIN MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 94. PHILIPPINES ANTITHROMBIN MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 95. PHILIPPINES ANTITHROMBIN MARKET SIZE, BY ROUTE, 2018-2030 (USD MILLION)
  • TABLE 96. PHILIPPINES ANTITHROMBIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 97. SINGAPORE ANTITHROMBIN MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 98. SINGAPORE ANTITHROMBIN MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 99. SINGAPORE ANTITHROMBIN MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 100. SINGAPORE ANTITHROMBIN MARKET SIZE, BY ROUTE, 2018-2030 (USD MILLION)
  • TABLE 101. SINGAPORE ANTITHROMBIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 102. SOUTH KOREA ANTITHROMBIN MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 103. SOUTH KOREA ANTITHROMBIN MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 104. SOUTH KOREA ANTITHROMBIN MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 105. SOUTH KOREA ANTITHROMBIN MARKET SIZE, BY ROUTE, 2018-2030 (USD MILLION)
  • TABLE 106. SOUTH KOREA ANTITHROMBIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 107. TAIWAN ANTITHROMBIN MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 108. TAIWAN ANTITHROMBIN MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 109. TAIWAN ANTITHROMBIN MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 110. TAIWAN ANTITHROMBIN MARKET SIZE, BY ROUTE, 2018-2030 (USD MILLION)
  • TABLE 111. TAIWAN ANTITHROMBIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 112. THAILAND ANTITHROMBIN MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 113. THAILAND ANTITHROMBIN MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 114. THAILAND ANTITHROMBIN MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 115. THAILAND ANTITHROMBIN MARKET SIZE, BY ROUTE, 2018-2030 (USD MILLION)
  • TABLE 116. THAILAND ANTITHROMBIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 117. VIETNAM ANTITHROMBIN MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 118. VIETNAM ANTITHROMBIN MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 119. VIETNAM ANTITHROMBIN MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 120. VIETNAM ANTITHROMBIN MARKET SIZE, BY ROUTE, 2018-2030 (USD MILLION)
  • TABLE 121. VIETNAM ANTITHROMBIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 122. EUROPE, MIDDLE EAST & AFRICA ANTITHROMBIN MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 123. EUROPE, MIDDLE EAST & AFRICA ANTITHROMBIN MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 124. EUROPE, MIDDLE EAST & AFRICA ANTITHROMBIN MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 125. EUROPE, MIDDLE EAST & AFRICA ANTITHROMBIN MARKET SIZE, BY ROUTE, 2018-2030 (USD MILLION)
  • TABLE 126. EUROPE, MIDDLE EAST & AFRICA ANTITHROMBIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 127. EUROPE, MIDDLE EAST & AFRICA ANTITHROMBIN MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 128. DENMARK ANTITHROMBIN MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 129. DENMARK ANTITHROMBIN MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 130. DENMARK ANTITHROMBIN MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 131. DENMARK ANTITHROMBIN MARKET SIZE, BY ROUTE, 2018-2030 (USD MILLION)
  • TABLE 132. DENMARK ANTITHROMBIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 133. EGYPT ANTITHROMBIN MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 134. EGYPT ANTITHROMBIN MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 135. EGYPT ANTITHROMBIN MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 136. EGYPT ANTITHROMBIN MARKET SIZE, BY ROUTE, 2018-2030 (USD MILLION)
  • TABLE 137. EGYPT ANTITHROMBIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 138. FINLAND ANTITHROMBIN MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 139. FINLAND ANTITHROMBIN MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 140. FINLAND ANTITHROMBIN MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 141. FINLAND ANTITHROMBIN MARKET SIZE, BY ROUTE, 2018-2030 (USD MILLION)
  • TABLE 142. FINLAND ANTITHROMBIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 143. FRANCE ANTITHROMBIN MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 144. FRANCE ANTITHROMBIN MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 145. FRANCE ANTITHROMBIN MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 146. FRANCE ANTITHROMBIN MARKET SIZE, BY ROUTE, 2018-2030 (USD MILLION)
  • TABLE 147. FRANCE ANTITHROMBIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 148. GERMANY ANTITHROMBIN MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 149. GERMANY ANTITHROMBIN MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 150. GERMANY ANTITHROMBIN MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 151. GERMANY ANTITHROMBIN MARKET SIZE, BY ROUTE, 2018-2030 (USD MILLION)
  • TABLE 152. GERMANY ANTITHROMBIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 153. ISRAEL ANTITHROMBIN MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 154. ISRAEL ANTITHROMBIN MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 155. ISRAEL ANTITHROMBIN MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 156. ISRAEL ANTITHROMBIN MARKET SIZE, BY ROUTE, 2018-2030 (USD MILLION)
  • TABLE 157. ISRAEL ANTITHROMBIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 158. ITALY ANTITHROMBIN MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 159. ITALY ANTITHROMBIN MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 160. ITALY ANTITHROMBIN MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 161. ITALY ANTITHROMBIN MARKET SIZE, BY ROUTE, 2018-2030 (USD MILLION)
  • TABLE 162. ITALY ANTITHROMBIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 163. NETHERLANDS ANTITHROMBIN MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 164. NETHERLANDS ANTITHROMBIN MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 165. NETHERLANDS ANTITHROMBIN MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 166. NETHERLANDS ANTITHROMBIN MARKET SIZE, BY ROUTE, 2018-2030 (USD MILLION)
  • TABLE 167. NETHERLANDS ANTITHROMBIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 168. NIGERIA ANTITHROMBIN MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 169. NIGERIA ANTITHROMBIN MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 170. NIGERIA ANTITHROMBIN MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 171. NIGERIA ANTITHROMBIN MARKET SIZE, BY ROUTE, 2018-2030 (USD MILLION)
  • TABLE 172. NIGERIA ANTITHROMBIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 173. NORWAY ANTITHROMBIN MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 174. NORWAY ANTITHROMBIN MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 175. NORWAY ANTITHROMBIN MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 176. NORWAY ANTITHROMBIN MARKET SIZE, BY ROUTE, 2018-2030 (USD MILLION)
  • TABLE 177. NORWAY ANTITHROMBIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 178. POLAND ANTITHROMBIN MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 179. POLAND ANTITHROMBIN MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 180. POLAND ANTITHROMBIN MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 181. POLAND ANTITHROMBIN MARKET SIZE, BY ROUTE, 2018-2030 (USD MILLION)
  • TABLE 182. POLAND ANTITHROMBIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 183. QATAR ANTITHROMBIN MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 184. QATAR ANTITHROMBIN MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 185. QATAR ANTITHROMBIN MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 186. QATAR ANTITHROMBIN MARKET SIZE, BY ROUTE, 2018-2030 (USD MILLION)
  • TABLE 187. QATAR ANTITHROMBIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 188. RUSSIA ANTITHROMBIN MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 189. RUSSIA ANTITHROMBIN MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 190. RUSSIA ANTITHROMBIN MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 191. RUSSIA ANTITHROMBIN MARKET SIZE, BY ROUTE, 2018-2030 (USD MILLION)
  • TABLE 192. RUSSIA ANTITHROMBIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 193. SAUDI ARABIA ANTITHROMBIN MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 194. SAUDI ARABIA ANTITHROMBIN MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 195. SAUDI ARABIA ANTITHROMBIN MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 196. SAUDI ARABIA ANTITHROMBIN MARKET SIZE, BY ROUTE, 2018-2030 (USD MILLION)
  • TABLE 197. SAUDI ARABIA ANTITHROMBIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 198. SOUTH AFRICA ANTITHROMBIN MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 199. SOUTH AFRICA ANTITHROMBIN MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 200. SOUTH AFRICA ANTITHROMBIN MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 201. SOUTH AFRICA ANTITHROMBIN MARKET SIZE, BY ROUTE, 2018-2030 (USD MILLION)
  • TABLE 202. SOUTH AFRICA ANTITHROMBIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 203. SPAIN ANTITHROMBIN MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 204. SPAIN ANTITHROMBIN MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 205. SPAIN ANTITHROMBIN MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 206. SPAIN ANTITHROMBIN MARKET SIZE, BY ROUTE, 2018-2030 (USD MILLION)
  • TABLE 207. SPAIN ANTITHROMBIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 208. SWEDEN ANTITHROMBIN MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 209. SWEDEN ANTITHROMBIN MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 210. SWEDEN ANTITHROMBIN MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 211. SWEDEN ANTITHROMBIN MARKET SIZE, BY ROUTE, 2018-2030 (USD MILLION)
  • TABLE 212. SWEDEN ANTITHROMBIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 213. SWITZERLAND ANTITHROMBIN MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 214. SWITZERLAND ANTITHROMBIN MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 215. SWITZERLAND ANTITHROMBIN MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 216. SWITZERLAND ANTITHROMBIN MARKET SIZE, BY ROUTE, 2018-2030 (USD MILLION)
  • TABLE 217. SWITZERLAND ANTITHROMBIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 218. TURKEY ANTITHROMBIN MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 219. TURKEY ANTITHROMBIN MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 220. TURKEY ANTITHROMBIN MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 221. TURKEY ANTITHROMBIN MARKET SIZE, BY ROUTE, 2018-2030 (USD MILLION)
  • TABLE 222. TURKEY ANTITHROMBIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 223. UNITED ARAB EMIRATES ANTITHROMBIN MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 224. UNITED ARAB EMIRATES ANTITHROMBIN MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 225. UNITED ARAB EMIRATES ANTITHROMBIN MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 226. UNITED ARAB EMIRATES ANTITHROMBIN MARKET SIZE, BY ROUTE, 2018-2030 (USD MILLION)
  • TABLE 227. UNITED ARAB EMIRATES ANTITHROMBIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 228. UNITED KINGDOM ANTITHROMBIN MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 229. UNITED KINGDOM ANTITHROMBIN MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 230. UNITED KINGDOM ANTITHROMBIN MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 231. UNITED KINGDOM ANTITHROMBIN MARKET SIZE, BY ROUTE, 2018-2030 (USD MILLION)
  • TABLE 232. UNITED KINGDOM ANTITHROMBIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 233. ANTITHROMBIN MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 234. ANTITHROMBIN MARKET, FPNV POSITIONING MATRIX, 2023